These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32805763)

  • 1. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
    BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
    von Landenberg N; Aziz A; von Rundstedt FC; Dobruch J; Kluth LA; Necchi A; Noon A; Rink M; Hendricksen K; Decaestecker KPJ; Seiler R; Poyet C; Fajkovic H; Shariat SF; Xylinas E; Roghmann F;
    Urol Oncol; 2018 May; 36(5):238.e19-238.e27. PubMed ID: 29506940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
    Ourfali S; Matillon X; Ricci E; Fassi-Fehri H; Benoit-Janin M; Badet L; Colombel M
    Eur Urol Focus; 2022 Sep; 8(5):1226-1237. PubMed ID: 34172421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
    Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
    Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
    Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
    EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC).
    Laukhtina E; Mostafaei H; D'Andrea D; Pradere B; Quhal F; Mori K; Miura N; Schuettfort VM; Sari Motlagh R; Aydh A; Abufaraj M; Karakiewicz PI; Enikeev D; Kimura S; Shariat SF
    World J Urol; 2021 Jun; 39(6):1961-1968. PubMed ID: 32808107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.
    Murakami K; Hamada A; Teramoto Y; Matsumoto K; Kita Y; Saito R; Yamasaki T; Matsui Y; Inoue T; Ogawa O; Kobayashi T
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1003-e1010. PubMed ID: 31402280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
    Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
    Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
    World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
    Xu S; Tan S; Wu T; Gu J; Xu L; Che X
    Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.